{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T16:28:09Z","timestamp":1786638489522,"version":"build-2736575974"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T00:00:00Z","timestamp":1712188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T00:00:00Z","timestamp":1712188800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005366","name":"University of Oslo","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005366","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardio-Oncology"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hodgkin\u2019s lymphoma (HL) is a hematological malignancy that affects both children and young adults. Traditional treatment is associated with a life-time prevalence of cardiac disease exceeding 50%. In the late 1990s protocols were modified to reduce cancer therapy-related adverse cardiac effects. This study aimed to assess the long-term impact of advances in treatment protocols on the cardiac health of HL survivors (HLS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      HLS (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009246) treated between 1997 and 2007 with anthracycline-based chemotherapy in three centers in Norway were included. Of these, 132 (53%) had also received mediastinal radiotherapy. HLS were compared to controls (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200958) recruited from the general population and matched for sex, age, smoking status, and heredity for coronary artery disease. All subjects underwent echocardiography, clinical assessment, and blood sampling.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The HLS were 46\u2009\u00b1\u20099 years old and had been treated 17\u2009\u00b1\u20093 years before inclusion in the study. There was no significant difference between HLS and controls in ejection fraction (EF) (58%\u00b15 vs. 59%\u00b14,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.08) or prevalence of heart failure. HLS treated with both anthracyclines and mediastinal radiotherapy (AC\u2009+\u2009MRT) had slightly worse left ventricular global longitudinal strain than controls (-19.3\u2009\u00b1\u20092.5% vs. -20.8\u2009\u00b1\u20092.0%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), but those treated with only anthracyclines did not. HLS treated with AC\u2009+\u2009MRT had a higher prevalence of valve disease than those treated only with anthracyclines (12% vs. 4%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>HLS treated with anthracyclines after the late 1990s have similar cardiac function and morphology as age-matched controls, apart from higher rates of valvular disease in those who also underwent mediastinal radiotherapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40959-024-00222-4","type":"journal-article","created":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T01:01:58Z","timestamp":1712192518000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Long-term cardiac effects of modern treatment for Hodgkin\u2019s lymphoma"],"prefix":"10.1186","volume":"10","author":[{"given":"Anders W","family":"Bjerring","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Knut HB","family":"Smeland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Stokke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina H","family":"Haugaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Espen","family":"Holte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Assami","family":"R\u00f6sner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilie E","family":"Kiserud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thor","family":"Edvardsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian Imre","family":"Sarvari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,4]]},"reference":[{"key":"222_CR1","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1001\/jamainternmed.2015.1180","volume":"175","author":"FA van Nimwegen","year":"2015","unstructured":"van Nimwegen FA, Schaapveld M, Janus CP, et al. Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk. JAMA Intern Med. 2015;175:1007\u201317.","journal-title":"JAMA Intern Med"},{"key":"222_CR2","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1016\/j.ejca.2010.02.010","volume":"46","author":"CE Kiserud","year":"2010","unstructured":"Kiserud CE, Loge JH, Foss\u00e5 A, Holte H, Cvancarova M, Foss\u00e5 SD. Mortality is persistently increased in Hodgkin\u2019s lymphoma survivors. Eur J Cancer. 2010;46:1632\u20139.","journal-title":"Eur J Cancer"},{"key":"222_CR3","doi-asserted-by":"publisher","first-page":"4801","DOI":"10.1002\/cam4.1572","volume":"7","author":"DJ Boyne","year":"2018","unstructured":"Boyne DJ, Mickle AT, Brenner DR, et al. Long-term risk of cardiovascular mortality in lymphoma survivors: a systematic review and meta-analysis. Cancer Med. 2018;7:4801\u201313.","journal-title":"Cancer Med"},{"key":"222_CR4","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1093\/annonc\/mdt156","volume":"24","author":"MV Maraldo","year":"2013","unstructured":"Maraldo MV, Brodin NP, Aznar MC, et al. Estimated risk of cardiovascular disease and secondary cancers with modern highly conformal radiotherapy for early-stage mediastinal Hodgkin lymphoma. Annals Oncology: Official J Eur Soc Med Oncol. 2013;24:2113\u20138.","journal-title":"Annals Oncology: Official J Eur Soc Med Oncol"},{"key":"222_CR5","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1016\/j.ijrobp.2011.09.020","volume":"83","author":"MV Maraldo","year":"2012","unstructured":"Maraldo MV, Brodin NP, Vogelius IR, et al. Risk of developing cardiovascular disease after involved node radiotherapy versus mantle field for Hodgkin lymphoma. Int J Radiat Oncol Biol Phys. 2012;83:1232\u20137.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"222_CR6","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa1000067","volume":"363","author":"A Engert","year":"2010","unstructured":"Engert A, Pl\u00fctschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin\u2019s lymphoma. N Engl J Med. 2010;363:640\u201352.","journal-title":"N Engl J Med"},{"key":"222_CR7","unstructured":"Lier registeret. Norway: Lier Kommune, 2019."},{"key":"222_CR8","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1080\/0284186X.2021.1917776","volume":"60","author":"SA Eikeland","year":"2021","unstructured":"Eikeland SA, Smeland KB, Mols F, et al. Chemotherapy-induced peripheral neuropathy after modern treatment of Hodgkin\u2019s lymphoma; symptom burden and quality of life. Acta Oncol (Stockholm Sweden). 2021;60:911\u201320.","journal-title":"Acta Oncol (Stockholm Sweden)"},{"key":"222_CR9","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1161\/CIRCULATIONAHA.105.169404","volume":"112","author":"SM Grundy","year":"2005","unstructured":"Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association\/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112:2735\u201352.","journal-title":"Circulation"},{"key":"222_CR10","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1001\/jama.2013.284427","volume":"311","author":"PA James","year":"2014","unstructured":"James PA, Oparil S, Carter BL, et al. 2014 evidence-based Guideline for the management of high blood pressure in adults: Report from the Panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311:507\u201320.","journal-title":"JAMA"},{"key":"222_CR11","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1161\/01.CIR.97.18.1837","volume":"97","author":"PW Wilson","year":"1998","unstructured":"Wilson PW, D\u2019Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837\u201347.","journal-title":"Circulation"},{"key":"222_CR12","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1093\/ehjci\/jev014","volume":"16","author":"RM Lang","year":"2015","unstructured":"Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2015;16:233\u201370.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"222_CR13","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1093\/ehjci\/jew082","volume":"17","author":"SF Nagueh","year":"2016","unstructured":"Nagueh SF, Smiseth OA, Appleton CP, et al. Recommendations for the evaluation of left ventricular diastolic function by Echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J - Cardiovasc Imaging. 2016;17:1321\u201360.","journal-title":"Eur Heart J - Cardiovasc Imaging"},{"key":"222_CR14","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42:3599\u2013726.","journal-title":"Eur Heart J"},{"key":"222_CR15","doi-asserted-by":"publisher","first-page":"3297","DOI":"10.1093\/eurheartj\/ehz641","volume":"40","author":"B Pieske","year":"2019","unstructured":"Pieske B, Tsch\u00f6pe C, de Boer RA, et al. How to diagnose heart failure with preserved ejection fraction: the HFA\u2013PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur Heart J. 2019;40:3297\u2013317.","journal-title":"Eur Heart J"},{"key":"222_CR16","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1016\/j.jcmg.2018.07.005","volume":"11","author":"H Yang","year":"2018","unstructured":"Yang H, Wright L, Negishi T, Negishi K, Liu J, Marwick TH. Research to practice. JACC Cardiovasc Imaging. 2018;11:1196\u2013201.","journal-title":"JACC Cardiovasc Imaging"},{"key":"222_CR17","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1093\/eurheartj\/ehab395","volume":"43","author":"A Vahanian","year":"2021","unstructured":"Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC\/EACTS guidelines for the management of valvular heart disease: developed by the Task Force for the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-thoracic surgery (EACTS). Eur Heart J. 2021;43:561\u2013632.","journal-title":"Eur Heart J"},{"key":"222_CR18","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1002\/cam4.655","volume":"5","author":"M Koshy","year":"2016","unstructured":"Koshy M, Fairchild A, Son CH, Mahmood U. Improved survival time trends in Hodgkin\u2019s lymphoma. Cancer Med. 2016;5:997\u20131003.","journal-title":"Cancer Med"},{"key":"222_CR19","doi-asserted-by":"crossref","unstructured":"Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS): Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC). Eur Heart J 2022;43:4229\u20134361.","DOI":"10.1093\/eurheartj\/ehac244"},{"key":"222_CR20","doi-asserted-by":"crossref","unstructured":"Biering-S\u00f8rensen T, Biering-S\u00f8rensen SR, Olsen FJ et al. Global longitudinal strain by Echocardiography predicts long-term risk of Cardiovascular Morbidity and Mortality in a low-risk General Population: the Copenhagen City Heart Study. Circulation Cardiovascular imaging 2017;10.","DOI":"10.1161\/CIRCIMAGING.116.005521"},{"key":"222_CR21","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.amjcard.2010.09.048","volume":"107","author":"HR Tsai","year":"2011","unstructured":"Tsai HR, Gjesdal O, Wethal T, et al. Left ventricular function assessed by two-dimensional speckle tracking echocardiography in long-term survivors of Hodgkin\u2019s lymphoma treated by mediastinal radiotherapy with or without anthracycline therapy. Am J Cardiol. 2011;107:472\u20137.","journal-title":"Am J Cardiol"},{"key":"222_CR22","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.1002\/cncr.11407","volume":"97","author":"SM Swain","year":"2003","unstructured":"Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin. Cancer. 2003;97:2869\u201379.","journal-title":"Cancer"},{"key":"222_CR23","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/djk064","volume":"99","author":"MJ Hooning","year":"2007","unstructured":"Hooning MJ, Botma A, Aleman BMP, et al. Long-term risk of Cardiovascular Disease in 10-Year survivors of breast Cancer. JNCI: J Natl Cancer Inst. 2007;99:365\u201375.","journal-title":"JNCI: J Natl Cancer Inst"},{"key":"222_CR24","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/j.jcmg.2018.05.012","volume":"11","author":"T Ferreira de Souza","year":"2018","unstructured":"Ferreira de Souza T, Quinaglia ACST, Osorio Costa F, et al. Anthracycline Therapy is Associated with Cardiomyocyte Atrophy and Preclinical manifestations of Heart Disease. JACC Cardiovasc Imaging. 2018;11:1045\u201355.","journal-title":"JACC Cardiovasc Imaging"},{"key":"222_CR25","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/S0735-1097(03)00759-9","volume":"42","author":"PA Heidenreich","year":"2003","unstructured":"Heidenreich PA, Hancock SL, Lee BK, Mariscal CS, Schnittger I. Asymptomatic cardiac disease following mediastinal irradiation. J Am Coll Cardiol. 2003;42:743\u20139.","journal-title":"J Am Coll Cardiol"},{"key":"222_CR26","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.jaccao.2021.09.015","volume":"3","author":"N van der Velde","year":"2021","unstructured":"van der Velde N, Janus CPM, Bowen DJ, et al. Detection of Subclinical Cardiovascular Disease by Cardiovascular Magnetic Resonance in Lymphoma survivors. JACC CardioOncol. 2021;3:695\u2013706.","journal-title":"JACC CardioOncol"},{"key":"222_CR27","doi-asserted-by":"publisher","first-page":"e004560","DOI":"10.1161\/CIRCHEARTFAILURE.117.004560","volume":"11","author":"JH Jordan","year":"2018","unstructured":"Jordan JH, Castellino SM, Mel\u00e9ndez GC, et al. Left ventricular Mass Change after Anthracycline Chemotherapy. Circ Heart Fail. 2018;11:e004560.","journal-title":"Circ Heart Fail"},{"key":"222_CR28","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1136\/heartjnl-2015-308765","volume":"102","author":"DM Gujral","year":"2016","unstructured":"Gujral DM, Lloyd G, Bhattacharyya S. Radiation-induced valvular heart disease. Heart. 2016;102:269\u201376.","journal-title":"Heart"},{"key":"222_CR29","doi-asserted-by":"publisher","first-page":"309","DOI":"10.3322\/caac.21341","volume":"66","author":"G Curigliano","year":"2016","unstructured":"Curigliano G, Cardinale D, Dent S, et al. Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management. CA Cancer J Clin. 2016;66:309\u201325.","journal-title":"CA Cancer J Clin"},{"key":"222_CR30","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1182\/blood-2006-07-034405","volume":"109","author":"BM Aleman","year":"2007","unstructured":"Aleman BM, van den Belt-Dusebout AW, De Bruin ML, et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood. 2007;109:1878\u201386.","journal-title":"Blood"},{"key":"222_CR31","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jacc.2022.04.042","volume":"80","author":"R Florido","year":"2022","unstructured":"Florido R, Daya NR, Ndumele CE, et al. Cardiovascular Disease Risk among Cancer survivors: the Atherosclerosis Risk in communities (ARIC) Study. J Am Coll Cardiol. 2022;80:22\u201332.","journal-title":"J Am Coll Cardiol"},{"key":"222_CR32","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1200\/JCO.2006.07.0805","volume":"25","author":"PA Heidenreich","year":"2007","unstructured":"Heidenreich PA, Schnittger I, Strauss HW, et al. Screening for coronary artery Disease after Mediastinal Irradiation for Hodgkin\u2019s Disease. J Clin Oncol. 2007;25:43\u20139.","journal-title":"J Clin Oncol"},{"key":"222_CR33","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1007\/s11764-018-0678-8","volume":"12","author":"THM Keegan","year":"2018","unstructured":"Keegan THM, Kushi LH, Li Q, et al. Cardiovascular disease incidence in adolescent and young adult cancer survivors: a retrospective cohort study. J Cancer Surviv. 2018;12:388\u201397.","journal-title":"J Cancer Surviv"},{"key":"222_CR34","doi-asserted-by":"publisher","first-page":"101744","DOI":"10.1016\/j.canep.2020.101744","volume":"67","author":"SD Foss\u00e5","year":"2020","unstructured":"Foss\u00e5 SD, Dahl AA, Myklebust T, et al. Risk of positive selection bias in longitudinal surveys among cancer survivors: lessons learnt from the national Norwegian testicular Cancer Survivor Study. Cancer Epidemiol. 2020;67:101744.","journal-title":"Cancer Epidemiol"}],"container-title":["Cardio-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40959-024-00222-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40959-024-00222-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40959-024-00222-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T01:04:35Z","timestamp":1712192675000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiooncologyjournal.biomedcentral.com\/articles\/10.1186\/s40959-024-00222-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,4]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["222"],"URL":"https:\/\/doi.org\/10.1186\/s40959-024-00222-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3759165\/v1","asserted-by":"object"}]},"ISSN":["2057-3804"],"issn-type":[{"value":"2057-3804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,4]]},"assertion":[{"value":"15 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was given by all study participants. The study complies with the Declaration of Helsinki and was approved by the Regional Committee for Medical Research Ethics (ref. 2016\/2311).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19"}}